Roche Reports Three-Year IMpower150 Data for Tecentriq in Non-Squamous NSCLC

Roche today presented three-year overall survival data from the Phase 3 IMpower150 trial evaluating Tecentriq (atezolizumab) plus bevacizumab and carboplatin/paclitaxel in patients with previously untreated metastatic non-squamous non-small cell lung cancer. The data showed that the overall survival benefit of Tecentriq was maintained at three years.